LIVE MARKET TRACKER :   BSE SENSEX        |    NSE NIFTY    
GLOBAL MARKETS :  NASDAQ      |    FSI London      |    NIKKEI Japan  
  USD GBP EUR CAD AUD INR
USD -
GBP -
EUR -
CAD -
AUD -
INR -
Indian-Commodity  :  Corporate  :  Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules

Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules (17-Aug-2016)

Lupin's US subsidiary, Gavis Pharmaceuticals LLC., USA (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million as per IMS MAT March 2016 data.

Lupin's Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.



Top News Today
Wintac gets nod for slump sale of pharmaceutical business undertaking
(27-Apr-2018)

Wintac gets nod for slump sale of pharmaceutical business undertakingWintac's board has approved the proposal to effect slump sale of the Pharmaceutical Business Undertaking of the company to Par Formulations. The board of directors of the company at their meeting held......click on news to read complete article.

Reliance Capital reports marginal rise in Q4 consolidated net profit
(27-Apr-2018)

Reliance Capital reports marginal rise in Q4 consolidated net profitReliance Capital has reported results for the fourth quarter and year ended March 31, 2018.The company has reported a rise of 36.77% in its net profit at Rs 212 crore for the quarter ended March 31, 2018......click on news to read complete article.

Capital India Finance planning to raise funds
(27-Apr-2018)

Capital India Finance planning to raise fundsCapital India Finance is planning to borrow/ raise funds in Indian/foreign currency by issue of debt securities, including but not limited to non-convertible debentures, bonds, MTN. The meeting of the......click on news to read complete article.

International Stock News
Asian markets trade mostly higher on Friday
(27-Apr-2018)

Asian markets trade mostly higher on FridayAll the Asian markets barring Shanghai Composite are trading in green terrain on Friday as investors' concerns over geopolitical risks eased on looming trade talks between the U.S. and China and the leaders......click on news to read complete article.

US markets closed higher; Dow logs best one-day gain in two weeks
(27-Apr-2018)

US markets closed higher; Dow logs best one-day gain in two weeksThe US markets closed higher on Thursday, with the Dow Jones Industrial Average booked its best one-day gain in about two weeks and the broader market all saw gains of at least 1% on the back of better-than-expected......click on news to read complete article.

Asian markets trade mostly lower in early deals on Thursday
(26-Apr-2018)

Asian markets trade mostly lower in early deals on ThursdayMost of the Asian equity benchmarks are trading lower in the early deals on Thursday, following the lackluster cues overnight from Wall Street. Though, Japan's Nikkei share average rose, buoyed by gains......click on news to read complete article.

 

     
  
Recent Corporate News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.